Dermatologic Oncology
Highlight Therapeutics S.L. focuses on clinical research in basal cell carcinoma, with interest in resectable primary disease and risk-adapted treatment settings.
- Basal cell carcinoma
- Resectable skin cancer
- Primary low-risk lesions
- Primary high-risk lesions
The sponsor’s trial activity is centered on intra-lesional therapy for localized tumor control in cutaneous malignancy.
Local Immunotherapy
Research activity includes the evaluation of BO-112 delivered by intra-lesional injection, reflecting a therapeutic interest in direct tumor-site treatment approaches.
- Intra-lesional administration
- Local immune activation
- Tumor-directed treatment
This area is aligned with localized intervention strategies for patients with surgically manageable basal cell carcinoma.
Oncology Clinical Development
The sponsor’s clinical research portfolio is concentrated in oncology, with emphasis on safety, tolerability, and early therapeutic activity in a single active cancer indication.
- Cutaneous oncology
- Therapeutic efficacy
- Clinical safety
Its current research footprint spans multiple collaborating sites within Spain, supporting clinical evaluation in a focused cancer setting.
